Learn more
This is not a comprehensive list of resources, and it is provided for reference only.
Single-gene diseases have been a primary focus of gene therapy research and development. These developments fulfill an urgent need. Gene therapy offers the possibility of going beyond managing symptoms to address the underlying causes of diseases.1
The US Food and Drug Administration (FDA) has approved several gene therapies. Other candidates are still in clinical development or are under review for approval.
Learn more about how Astellas Gene Therapies is developing investigational gene therapy treatments for Pompe disease, X-linked myotubular myopathy (XLMTM) and myotonic dystrophy type 1 (MDT1).
Note: The table below does not contain an exhaustive list for gene therapy research, as this area continues to evolve. Except where FDA approval is noted in the table, other research programs are investigational treatments for which safety and efficacy are not yet established and there is no guarantee that they will be approved by the FDA.
Gene therapies under development. Click to see available therapies.
Sickle cell disease
Hemophilia A and B, other clotting disorders
Etranacogene dezaparvovec-drlb, AAV, FDA approved 2022
Betibeglogene autotemcel, LV, FDA approved 2022
Severe anemias
Nadofaragene firadenovec-vncg, AV, FDA approved 2022
Some lymphomas
Axicabtagene ciloleucel, CAR T cell therapy, FDA approved 2017
Brexucabtagene autoleucel, CAR T cell therapy, FDA approved 2020
Lisocabtagene maraleucel, CAR T cell therapy, FDA approved 2022
Tisagenlecleucel, CAR T cell therapy, FDA approved 2017
Some leukemias
Brexucabtagene autoleucel, CAR T cell therapy, FDA approved 2020
Talimogene laherparepvec, genetically modified viral therapy, FDA approved 2015
Ciltacabtagene autoleucel, CAR T cell therapy, FDA approved 2022
Idecabtagene vicleucel, CAR T cell therapy, FDA approved 2021
Voretigene neparvovec-rzyl, AAV, FDA approved 2017
Hereditary angioedema
Pompe disease
Huntington's disease
Frontotemporal dementia
Parkinson's disease
Alzheimer's disease
Elivaldogene autotemcel, LV, FDA approved 2022
Duchenne muscular dystrophy
Myotonic dystrophy
Onasemnogene abeparvovec-xioi, AAV gene replacement therapy, FDA approved 2019
X-linked myotubular myopathy (XLMTM)
Who is eligible to receive gene therapy depends on many different factors. Gene therapies approved by the FDA have a statement indicating when and how they can be used. Some of the variables affecting who can use a particular drug include:
A genetic test may identify a genetic disease by detecting gene variants. A genetic test can help confirm a genetic disease or uncover a person’s chance of developing or passing on a genetic disease.
This is not a comprehensive list of resources, and it is provided for reference only.